JP2005514906A - ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 - Google Patents

ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 Download PDF

Info

Publication number
JP2005514906A
JP2005514906A JP2003502178A JP2003502178A JP2005514906A JP 2005514906 A JP2005514906 A JP 2005514906A JP 2003502178 A JP2003502178 A JP 2003502178A JP 2003502178 A JP2003502178 A JP 2003502178A JP 2005514906 A JP2005514906 A JP 2005514906A
Authority
JP
Japan
Prior art keywords
lce
assay
assay system
agent
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003502178A
Other languages
English (en)
Japanese (ja)
Inventor
フリードマン，ローリ
プラウマン，グレゴリー，ディー．
ベルビン，マーシャ
フランシス−ラング，ヘレン
リー，ダンクシー
フンケ，ロール，ピー．
カリーム，フェリックス，ディー．
キース，リンダ，エヌ．
コブリツェック，トーマス，アイ．
Original Assignee
エクセリクシス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エクセリクシス・インコーポレイテッド filed Critical エクセリクシス・インコーポレイテッド
Publication of JP2005514906A publication Critical patent/JP2005514906A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4739—Cyclin; Prad 1
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2003502178A 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法 Withdrawn JP2005514906A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29607601P 2001-06-05 2001-06-05
US32860501P 2001-10-10 2001-10-10
US35725302P 2002-02-15 2002-02-15
US36119602P 2002-03-01 2002-03-01
PCT/US2002/017739 WO2002099068A2 (fr) 2001-06-05 2002-06-03 Lce utilises comme modificateurs de la voie p53 et procede d'utilisation

Publications (1)

Publication Number Publication Date
JP2005514906A true JP2005514906A (ja) 2005-05-26

Family

ID=27501675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003502009A Withdrawn JP2004532638A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＭＡＰ３Ｋｓおよび使用方法
JP2003502178A Withdrawn JP2005514906A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003502009A Withdrawn JP2004532638A (ja) 2001-06-05 2002-06-03 ｐ５３経路のモディファイヤーとしてのＭＡＰ３Ｋｓおよび使用方法

Country Status (5)

Country Link
EP (2) EP1402051A4 (fr)
JP (2) JP2004532638A (fr)
AU (1) AU2002314887A1 (fr)
CA (2) CA2448112A1 (fr)
WO (4) WO2002098891A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2012233044B2 (en) * 2002-11-22 2015-09-03 Ganymed Pharmaceuticals Ag Genetic products differentially expressed in tumors and the use thereof
JP2006517788A (ja) * 2002-12-20 2006-08-03 ミレニアム・ファーマシューティカルズ・インコーポレイテッド １５９８６、２１８８、２０７４３、９１４８、９１５１、９７９１、４４２５２、１４１８４、４２４６１、８２０４、７９７０、２５５５２、２１６５７、２６４９２、２４１１、１５０８８、１９０５、２８８９９、６３３８０、３３９３５、１０４８０、１２６８６、２５５０１、１７６９４、１５７０１、５３０６２、４９９０８、２１６１２、３８９４９、６２１６、４６８６３、９２３５、２２０１、６９８５、９８８３、１２２３８、１８０５７、２１６１７、３９２２８、４９９２８、５４４７６、６２１１３、６４３１６、１２２６４、３２３６２、５８１９８、２８８７、３２０５、８５５７、９６００、９６９３、４４８６７、５３０５８、５５５５６、５７６５８、２２０８、１０２５２、１０３０２、１４２１８、３３８７７、１０３１７、１０４８５、２５９６４、１４８１５、１３６３、１３９７、１４８２７、２１７０８、３８０１、６４６９８、２１７９または１３２４９を使用する癌を処置するための方法および組成物
DE10316701A1 (de) * 2003-04-09 2004-11-04 Hinzmann, Bernd, Dr. Humane Nukleinsäuresequenzen aus Bronchialkarzinomen
JPWO2005005665A1 (ja) * 2003-07-11 2006-11-09 萬有製薬株式会社 Ｌｃｅによる肥満治療に有効な化合物の評価方法
EP1677739A4 (fr) * 2003-09-04 2008-07-23 Immusol Inc Methodes permettant d'identifier des agents qui inhibent la croissance des cellules cancereuses
WO2005083425A2 (fr) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Agents de diagnostic et de therapie destines aux maladies associees a la proteine kinase 13 activee par un mitogene (map3k13)
KR101429098B1 (ko) 2004-06-04 2014-09-22 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 인쇄가능한 반도체소자들의 제조 및 조립방법과 장치
WO2008143635A1 (fr) 2007-01-17 2008-11-27 The Board Of Trustees Of The University Of Illinois Systèmes optiques fabriqués par un ensemble à base d'impression
US8865489B2 (en) 2009-05-12 2014-10-21 The Board Of Trustees Of The University Of Illinois Printed assemblies of ultrathin, microscale inorganic light emitting diodes for deformable and semitransparent displays
US9442285B2 (en) 2011-01-14 2016-09-13 The Board Of Trustees Of The University Of Illinois Optical component array having adjustable curvature
US9765934B2 (en) 2011-05-16 2017-09-19 The Board Of Trustees Of The University Of Illinois Thermally managed LED arrays assembled by printing
WO2012167096A2 (fr) 2011-06-03 2012-12-06 The Board Of Trustees Of The University Of Illinois Réseau d'électrodes de surface conformables, multiplexées de manière active et à haute densité, pour un interfaçage avec le cerveau
KR101979354B1 (ko) 2011-12-01 2019-08-29 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 프로그램 변형을 실행하도록 설계된 과도 장치
CN114181944B (zh) * 2020-09-14 2023-10-03 中国科学院动物研究所 突变基因及构建短肢性侏儒症小型猪模型的方法和用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0572478T3 (da) * 1991-02-22 2006-01-16 Inst Medical W & E Hall HBGAD- og HIGAD-polypeptider og nukleinsyre og anvendelse heraf til diagnostik og behandling af GAD-autoantigen-associerede sygdomme
US5405941A (en) * 1993-04-15 1995-04-11 National Jewish Center For Immunology And Respiratory Medicine MEKK protein, capable of phosphorylating MEK
US5554523A (en) * 1994-03-01 1996-09-10 Children's Hospital Of Philadelphia Nucleic acid sequences encoding human leucine-zipper protein-kinase
WO1999041385A1 (fr) * 1998-02-13 1999-08-19 Cadus Pharmaceutical Corporation Proteines mekk1 et leurs fragments destines a etre utilises dans la regulation d'une apoptose
WO1999047686A2 (fr) * 1998-03-16 1999-09-23 Cadus Pharmaceutical Corporation Proteines humaines mekk, molecules d'acides nucleiques et procedes d'utilisation correspondants
EP1161542A1 (fr) * 1999-03-18 2001-12-12 University Of Bristol Elongase d'acides gras polyinsatures tires de caenorhabiditis elegans
AU4483500A (en) * 1999-04-23 2000-11-10 Incyte Genomics, Inc. Human membrane-associated proteins
WO2001007586A2 (fr) * 1999-07-22 2001-02-01 The University Of British Columbia Enzyme biosynthetique d'acides gras a chaines longues de plantes
AU1472801A (en) * 1999-11-12 2001-06-06 Human Genome Sciences, Inc. 24 human secreted proteins
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
CA2409778A1 (fr) * 2000-06-20 2001-12-27 Incyte Genomics, Inc. Proteines secretees
AU9174501A (en) * 2000-08-11 2002-02-25 Merck Patent Gmbh Novel mitogen activated kinase
JP2004513662A (ja) * 2000-11-29 2004-05-13 キセノン　ジェネティックス　インコーポレイテッド ヒトエロンガーゼ遺伝子、その使用およびそれを調節する化合物
CA2437571A1 (fr) * 2001-02-06 2002-08-15 Incyte Genomics, Inc. Recepteurs et proteines associees aux membranes
WO2002062975A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine du type elongase hselo1
WO2002062974A2 (fr) * 2001-02-08 2002-08-15 Bayer Aktiengesellschaft Regulation de la proteine humaine elongase hselo1
WO2002096943A1 (fr) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Genes activant le stat6
AU2003231531A1 (en) * 2002-04-24 2003-11-10 Incyte Corporation Kinases and phosphatases

Also Published As

Publication number Publication date
JP2004532638A (ja) 2004-10-28
AU2002314887A1 (en) 2002-12-16
WO2002098889A3 (fr) 2003-03-27
EP1402262A4 (fr) 2005-05-11
WO2002098889A2 (fr) 2002-12-12
WO2002099068A2 (fr) 2002-12-12
EP1402051A2 (fr) 2004-03-31
WO2002098891A3 (fr) 2003-05-30
EP1402051A4 (fr) 2005-08-17
WO2002098891A2 (fr) 2002-12-12
CA2449479A1 (fr) 2002-12-12
CA2448112A1 (fr) 2002-12-12
WO2002099068A3 (fr) 2003-12-04
WO2002098468A1 (fr) 2002-12-12
EP1402262A2 (fr) 2004-03-31

Similar Documents

Publication Publication Date Title
US20050112568A1 (en) Dgks as modifiers of the p53 pathwha and methods of use
US20100325743A1 (en) Marks as modifiers of the p53 pathway and methods of use
US20060252035A1 (en) Sphks as modifiers of the p53 pathway and methods of use
JP2009082131A (ja) ｐ２１経路のモディファイヤーとしてのＨＡＤＨｓおよび使用方法
JP2005514906A (ja) ｐ５３経路のモディファイヤーとしてのＬＣＥｓおよび使用方法
JP2007502115A (ja) ＲＡＣ経路のモディファイヤーとしてのＭＥＬＫｓおよび使用方法
JP2005512529A (ja) βカテニン経路のモディファイヤーとしてのＴＡＯＪＩＫｓおよび使用方法
JP2004528045A (ja) ｐ５３経路のモディファイヤーとしてのＰ５ＣＲｓおよび使用方法
JP2007526746A (ja) ＰＴＥＮ経路のモディファイヤーとしてのＭＡＲＫｓおよび使用方法
JP2006513698A (ja) ｐ２１経路のモディファイヤーとしてのＦＬＪ２０６４７および使用方法
JP2005534324A (ja) ＡＸＩＮ経路のモディファイヤーとしてのＰＡＰＳＳｓおよび使用方法
JP2005506844A (ja) ｐ５３経路のモディファイヤーとしてのＬＲＲＣＡＰＳ及び使用方法
JP4646631B2 (ja) ＲＢ経路のモディファイヤーとしてのＣＣＴ６ｓおよび使用方法
JP2007502118A (ja) βカテニン経路のモディファイヤーとしてのＳＵＬＦｓ及び使用方法
US20070134732A1 (en) Lces as modifiers of the p53 pathway and methods of use
JP2005516583A (ja) ｐ５３経路のモディファイヤーとしてのＡＤＳＬｓおよび使用方法
US20050227228A1 (en) Map3ks as modifiers of the p53 pathway and methods of use
JP2005534335A (ja) Ｒｂ経路のモディファイヤーとしてのｐｓｍｃおよび使用方法
JP2005534334A (ja) ｐ２１経路のモディファイヤーとしてのＣＳＮＫ１ＧＳおよび使用方法
JP2006516096A (ja) ＲＡＣ経路のモディファイヤーとしてのＣＳＮＫｓおよび使用方法
JP2007516703A (ja) βカテニン経路のモディファイヤーとしてのＰＬＫｓ及び使用方法
JP2006517395A (ja) Ａｘｉｎ経路のモディファイヤーとしてのｆｌｊ１０６０７および使用方法
JP2005538723A (ja) ＣＨＫ経路のモディファイヤーとしてのＰＡＫｓおよび使用方法
AU2002303971A1 (en) LCEs as modifiers of the p53 pathway and methods of use
JP2007525964A (ja) ｐ５３経路のモディファイヤーとしてのＳＰＰＬｓおよび使用方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050526

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070308